NCT03421743View on ClinicalTrials.gov

Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

October 15, 2019

Study Completion Date

January 13, 2020

Conditions
Mycobacterium Infections, Nontuberculous
Interventions
DRUG

Inhaled molgramostim

300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation

DRUG

Antimycobacterial regimen

Multidrug NTM guideline-based antimycobacterial regimen

Trial Locations (5)

2139

Concord Repatriation General Hospital, Concord

4032

The Prince Charles Hospital, Chermside West

4120

Greenslopes Private Hospital, Greenslopes

6000

Royal Perth Hospital, Perth

SW3 6NP

Royal Brompton Hospital, London

All Listed Sponsors
lead

Savara Inc.

INDUSTRY

NCT03421743 - Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection | Biotech Hunter | Biotech Hunter